AstraZeneca 100220
The FDA granted Farxiga in the US.
Share this:
AstraZeneca, a global biopharmaceutical company, announced that its Farxiga (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for patients with chronic kidney disease.
From a chartist point of view, on a daily chart, prices are stuck below the resistance at 8848. The 50 day MA is negatively oriented above prices while the RSI is in bearish territory. As long as the 8848 resistance is not broken, readers may therefore consider further downside towards 7930 and 7121 in extension.
From a chartist point of view, on a daily chart, prices are stuck below the resistance at 8848. The 50 day MA is negatively oriented above prices while the RSI is in bearish territory. As long as the 8848 resistance is not broken, readers may therefore consider further downside towards 7930 and 7121 in extension.
Source : TradingVIEW, Gain Capital
AstraZeneca, a global biopharmaceutical company, announced that its Farxiga (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for patients with chronic kidney disease.
From a chartist point of view, on a daily chart, prices are stuck below the resistance at 8848. The 50 day MA is negatively oriented above prices while the RSI is in bearish territory. As long as the 8848 resistance is not broken, readers may therefore consider further downside towards 7930 and 7121 in extension.
From a chartist point of view, on a daily chart, prices are stuck below the resistance at 8848. The 50 day MA is negatively oriented above prices while the RSI is in bearish territory. As long as the 8848 resistance is not broken, readers may therefore consider further downside towards 7930 and 7121 in extension.
Source : TradingVIEW, Gain Capital
Related tags:
Latest market news
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.